Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect
- PMID: 31784703
- PMCID: PMC7414036
- DOI: 10.1038/s41433-019-0722-6
Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect
Conflict of interest statement
The authors declare that they have no conflict of interest.
References
-
- US FDA. Biological Product Definitions. FDA. https://www.fda.gov/media/108557/download. Accessed 25 Oct 2019.
-
- The Vision Academy Steering Committee. Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–73. doi: 10.1007/s00417-017-3647-4. - DOI - PMC - PubMed
-
- Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5. - PubMed